|clinical significance of reductions in HIV susceptibility
Oct 5, 1999
What is the clinical significance of the reported fold changes in HIV susceptibility to various antiretroviral agents in response to HIV codon mutations? Can a drug that HIV has, for example, a 5-fold reduction in susceptibilty to still be clinically effective?
| Response from Dr. Holodniy
Indeed it may, combined with other agents which have equal or greater potency and/or lack of resistance. In addition, certain mutations which confer resistance (genotypic and phenotypic) to one agent, may enhance the activity of other agents. For instance a codon 184 mutation confering high level resistance to 3TC, can rescue back activity of AZT when AZT resistance is present. MH
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.